Please login to the form below

Not currently logged in
Email:
Password:

Effexor XR generic approved

The US Food and Drug Administration (FDA) has approved the first generic version of Pfizer's anti-depressant Effexor XR (venlafaxine)

The US Food and Drug Administration (FDA) has approved the first generic version of Pfizer's Effexor XR (venlafaxine) capsules, a widely used anti-depressant with annual sales of about $2.75bn in the US.

The branded drug, which was launched by Wyeth (now Pfizer) in 1993, is approved in the US for major depressive disorder and generalised anxiety disorder and is used off-label for indications including diabetic neuropathy and migraine.

The generic version of the capsules, made by Teva Pharmaceuticals, will begin shipping on July 1. That date is specified under a "pay for delay" patent settlement between Teva and Wyeth signed in 2006.

Teva will have 180 days of US marketing exclusivity for the generic product under a law that awards exclusivity to the first company to file an Abbreviated New Drug Application (ANDA) containing a patent challenge called a paragraph IV certification.

Like branded Effexor XR capsules, the generic product will carry a number of cautions, including a boxed warning indicating that anti-depressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.

30th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics